Greenup Street Wealth Management LLC Buys New Position in DexCom, Inc. $DXCM

Greenup Street Wealth Management LLC bought a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 34,043 shares of the medical device company’s stock, valued at approximately $2,259,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in DXCM. SJS Investment Consulting Inc. grew its stake in DexCom by 4,800.0% in the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after purchasing an additional 384 shares during the period. Financial Consulate Inc. purchased a new stake in DexCom in the third quarter worth $29,000. CVA Family Office LLC grew its stake in DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after purchasing an additional 147 shares during the period. ORG Partners LLC grew its stake in DexCom by 124.3% in the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after purchasing an additional 281 shares during the period. Finally, Spire Wealth Management grew its stake in DexCom by 113.8% in the fourth quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock worth $38,000 after purchasing an additional 305 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Price Performance

NASDAQ DXCM opened at $64.02 on Friday. DexCom, Inc. has a one year low of $54.11 and a one year high of $89.98. The stock has a 50-day moving average of $68.20 and a 200 day moving average of $66.90. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.59 and a current ratio of 1.88. The company has a market capitalization of $24.64 billion, a price-to-earnings ratio of 30.49, a PEG ratio of 1.25 and a beta of 1.55.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.03. The business had revenue of $1.26 billion for the quarter, compared to analysts’ expectations of $1.25 billion. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The business’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.45 EPS. On average, sell-side analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Ratings Changes

DXCM has been the topic of several recent research reports. Piper Sandler reaffirmed an “overweight” rating on shares of DexCom in a research note on Thursday, February 5th. Weiss Ratings raised DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, March 4th. Evercore raised DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price target on the stock in a research note on Tuesday, March 24th. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $86.00 price target (up from $84.00) on shares of DexCom in a research note on Friday, January 9th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $85.00 price target on shares of DexCom in a research note on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, DexCom presently has an average rating of “Moderate Buy” and a consensus price target of $86.50.

Insider Transactions at DexCom

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $64.85, for a total transaction of $110,245.00. Following the transaction, the executive vice president owned 112,904 shares in the company, valued at approximately $7,321,824.40. This represents a 1.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.32% of the company’s stock.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.